A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus

Summary

The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in participants With Lichen Sclerosus. This is randomized, double-blind, vehicle-controlled (DBVC) study with a DBVC period of 12 weeks followed by an open label period (OLE) period of 12 weeks.

Timeline

Start

2022-11-18

Primary completion

2023-09-01

Completion

2023-12-21

Outcome

Missed primary endpoint

registry p = 0.737 NCT05593445 ↗

Drugs

Indications